Efficacy of Thiamine in the Treatment of Postcardiac Arrest Patients: A Randomized Controlled Study
Table 2
Primary and secondary outcomes of out-of-hospital cardiac arrest (OHCA) patients receiving thiamine or placebo.
Outcome
Thiamine (n = 20)
Placebo (n = 17)
Relative risk (95% CI)
value
Primary outcome
28-day mortality
10 (50)
8 (47.1)
1.06 (0.54–2.07)
0.86
Secondary outcome
Good neurological outcome (CPC 1 or 2 at discharge)
7 (35)
4 (23.5)
1.27 (0.71–2.23)
0.45
S100B level at 72 ha median (IQR) (ng/L)
0.126 (0.085–0.349)
0.168 (0.073–0.987)
—
0.81
Lactate level at 24 h, median (IQR) (mmol/L)
2.3 (1.5–5.6)
2.6 (2–4.4)
—
0.35
Lactate level at 48 h, median (IQR) (mmol/L)
2 (1.5–3.7)
2 (1.4–2.2)
—
0.76
Lactate level at 72 hb, median (IQR) (mmol/L)
1.6 (1.1–2.5)
1.5 (1–1.8)
—
0.24
Lactate clearance at 24 h, median (IQR) (%)
59.7 (34.1–80.2)
53.3 (41.5–69.6)
—
0.52
Lactate clearance at 48 h, median (IQR) (%)
75.2 (34.1–80.8)
67.1 (57.2–74.4)
—
0.70
Lactate clearance at 72 h, median (IQR) (%)
74.8 (47.5–84.4)
75 (64.4–82.8)
—
0.69
ICU length of stay (days)
7 (5–9)
5 (3–7)
—
0.18
aS100B levels at 72 h were collected in 19 patients from the thiamine group and 12 patients from the placebo group. bLactate levels at 72 h were collected in 16 patients from the thiamine group and 12 patients from the placebo group. Some patients either did not have a second or third lactate sampling or the results were missing or otherwise unavailable. Data are presented as medians (IQR) unless otherwise specified. CI, confidence interval; CPC, cerebral performance category; ICU, intensive care unit; IQR, interquartile range.
